{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 56,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a biological signaling pathway map to justify combination therapy strategy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/24",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.48,
        "x": 0.08,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Biological pathway map showing interactions between RTKs, RAS, RAF, MEK, ERK, and PI3K/AKT/mTOR pathways.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9af6f18-4497-4433-bf6a-97c911307067",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.3
      },
      "kind": "list",
      "text": "Potential Naporafenib combos with Erasca Pipeline: naporafenib + ERAS-007, naporafenib + ERAS-601, naporafenib + ERAS-007 + ERAS-601",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d269db90-7d93-4371-a762-fb7e67e0f1f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.55,
        "y": 0.6
      },
      "kind": "table",
      "text": "Target Tumor Types: NF1 LOF Tissue Agnostic, RAS G13R Tissue Agnostic, BRAF Class 2 Tissue Agnostic, BRAF Class 3 Tissue Agnostic",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbe95db5-fb2d-4975-8482-46004c216aa1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Naporafenib could combine synergistically with the rest of our pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe6fd3c6-46bb-45bd-ab49-416a36495306",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 16,
      "beatId": "de59f7d9-38c9-46a9-8877-a3655888462f",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Erasca's pipeline and clinical data",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Slides 16-42 present Erasca's pipeline and clinical data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}